Biofrontera Inc. reaffirmed revenue guidance for the full year 2023. The company affirms expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +6.35% | +23.08% | -33.57% |
Mar. 18 | Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024 | |
Mar. 15 | Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.57% | 9.36M | |
+34.00% | 704B | |
+27.39% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.09% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- BFRI Stock
- News Biofrontera Inc.
- Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023